Insilico Medicine is pleased to announce that it has entered into a research collaboration with Pfizer Inc. (NYSE: PFE) to utilize Insilico's machine learning technology and proprietary Pandomics Discovery Platform with the aim of identifying real-world evidence for potential therapeutic targets implicated in a variety of diseases.
Insilico is advancing its latest target identification systems utilizing machine learning, generative biology methods, and synthetic data generation pipelines, and we are pleased to be collaborating with Pfizer on its target identification efforts. Alex Zhavoronkov, PhD, founder, and CEO of Insilico Medicine
We look forward to working with Insilico as Pfizer continues to explore new technologies that may be able to help us identify targets and biomarkers that could assist in our discovery programs, and potentially lead to breakthrough therapeutics for patients with unmet medical needs. Morten Sogaard, Vice President, Target Sciences, Pfizer
In September 2019, Insilico Medicine announced a $37 million round led by prominent biotechnology and AI investors. Source:
Also in Industry News
How to decide whether or not to start treatment for prostate cancer?
Analysis of the SARS-CoV-2 proteome via visual tools
$65m investment increases British Patient Capital’s exposure to life sciences and health technology